- Siemens Healthineers’ 2Q Adjusted Ebit was EU822 million, showing a growth of +7.6% from the previous year, but fell short of the expected EU841.3 million.
- The company’s Imaging adjusted Ebit was EU598 million, decreasing by -4.8% compared to last year, and below the anticipated EU648.3 million.
- The Diagnostics adjusted Ebit showed improvement, turning a previous year’s loss of EU33 million into a gain of EU45 million. This surpassed the estimated EU37.5 million.
- The Advanced Therapies division’s adjusted Ebit grew marginally by +1.2% to EU85 million, slightly above the estimate of EU83 million.
- Total revenue was EU5.44 billion, growing by +1.7% from last year, but narrowly missed the estimate of EU5.49 billion.
- Sales for the Imaging, Advanced Therapies and Diagnostics divisions came in at EU2.96 billion, EU526 million and EU1.10 billion respectively; Diagnostics showed the most growth (+2.1%) but all three missed their estimated figures.
- EPS was EU0.38, significantly higher than the previous year’s EU0.090 but lower than the estimated EU0.44.
- Free cash flow was notably low at EU120 million, representing a -77% decline from the previous year.
- Varian sales decreased by -2.6% to EU910 million, while its adjusted Ebit goes up +10% to EU149 million, slightly above estimate.
- The year forecast remains unchanged, with comparable sales still expected to grow by +4.5% to +6.5%, and adjusted EPS projected to be between EU2.10 to EU2.30.
- Siemens Healthineers has increased its margin expectation for the Diagnostics segment, now forecasting an adjusted EBIT margin of between 4% and 6%, up from the previous 2.5% to 4.5%.
A look at Siemens Healthineers Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Siemens Healthineers, a leading medical technology company, is positioned for future growth and success based on its Smartkarma Smart Scores. With a solid Momentum score of 4, the company shows strong potential for continued upward movement in the market. Additionally, Siemens Healthineers earns respectable scores in Dividend and Growth at 3 each, indicating a balanced approach to rewarding shareholders and pursuing expansion opportunities. While Value and Resilience scores come in at 2, suggesting areas for improvement, the overall outlook for Siemens Healthineers appears positive as it continues to innovate and adapt in the ever-evolving healthcare industry.
Siemens Healthineers operates globally, providing essential medical imaging, laboratory diagnostics, and digital health solutions to enhance healthcare delivery. The company’s commitment to innovation and comprehensive services places it at the forefront of the medical technology sector. With a diverse range of offerings, Siemens Healthineers is well-positioned to drive growth and deliver value to its stakeholders over the long term, supported by its solid Smartkarma Smart Scores across multiple key factors.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
